3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
137
INDUSTRY
33
NIH
25
NETWORK
4
OTHER_GOV
3
FED
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Classical hematology
1
Conditions
Prostatic Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Fanconi Anemia, Complementation Group N
1
Fanconi Anemia, Complementation Group D1
1
Interventions
pembrolizumab
3
enzalutamide
3
Abiraterone Acetate
3
apalutamide
2
Topotecan
2
Testosterone
2
Itraconazole
2
Docetaxel
2
Cholecalciferol
2
Celecoxib
2
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
2
zanubrutinib
1
venetoclax
1
talabostat
1
sargramostim
1
pasireotide
1
olaparib
1
leucoselect phytosome
1
ibrutinib
1
capivasertib
1
acalabrutinib
1
abiraterone
1
Tablets
1
Streptozocin
1
Rituximab
1
Radiosurgery
1
Pluvicto
1
PT-100 dipeptide
1
Oxaliplatin
1
Nivolumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
FED
×
olaparib
×
Clear all
NCT04038502
2025-08-20
COBRA
VA Office of Research and Development
Phase 2
Recruiting
100 enrolled